Zhuding International Limited Signs Reverse Merger Agreement with Automated Water Solutions Inc. and Belisarian Holdings
HERTS, United Kingdom, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Zhuding International Limited (OTC:…
VERSES Closes Second Tranche of LIFE Offering Bringing Aggregate Funds Raised to $5.2M From Recent Offerings
November 15, 2024 20:51 ET | Source: VERSES AI Inc. THIS NEWS…
Nvni Group Limited Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Nvni Group Limited (Nasdaq:…
Update on the privatisation of Humo payments system in Uzbekistan
November 15, 2024 16:15 ET | Source: JSC Kaspi.kz ALMATY, Kazakhstan, Nov.…
AppTech Payments Reports Third Quarter 2024 Results and Provides Business Update
CARLSBAD, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ:…
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen…
